Thiazole, 2-Bromo-5-Chloro-

The incorporation of a 5-chloro-2-thiazolyl moiety into early-stage kinase inhibitor backbones often proceeds via Suzuki-Miyaura cross-coupling of 2-bromo-5-chlorothiazole with aryl boronic acids bearing pendant solubility-enhancing groups. Process development teams utilising this building block in multi-kilogram campaigns encounter a kinetic selectivity bottleneck: oxidative addition of Pd(0) at the C–Br bond is significantly faster than insertion at C–Cl, yet competitive dehalogenation side reactions generate detectable levels (typically 3–5 area% by calibrated HPLC) of the 2-H-5-chlorothiazole contaminant if dissolved oxygen concentration in the reaction mass exceeds 0.5 mg/L. Accordingly, production protocols specified for a pilot-scale 200 L glass-lined reactor mandate sparging with argon (O₂ ≤5 ppm) prior to catalyst injection, followed by maintenance of a positive nitrogen blanket during the entire heating cycle to 65 °C. The catalyst system, frequently a combination of Pd(OAc)₂ (0.05–0.2 mol%) and SPhos ligand (0.1–0.4 mol%), is pre-formed in anhydrous toluene before charging; excursions above 0.3 mol% palladium loading correlate with an increase in homocoupled thiazole dimer impurity to levels requiring additional hot filtration through a 0.5 µm sintered stainless steel candle filter. The mass recovery filter cake, composed primarily of the dimer and residual palladium black, is disposed of as Category 5.1 hazardous waste in accordance with EU Directive 2008/98/EC. Compliance with ICH Q7 Section 7.3 (Materials Management) necessitates retention samples of each batch of the thiazole intermediate, with specification limits for HPLC purity ≥99.0% and total palladium residue ≤10 ppm as determined by ICP-MS per USP ⟨233⟩. The recommended molar feed ratio of 2-bromo-5-chlorothiazole to boronic acid is 1.00–1.05; excess above 1.10 equivalents results in an accumulation of unreacted thiazole that complicates work-up partitioning and increases E-factors, while excess boronic acid leads to protodeboronation side products that co-crystallise in the product. Aqueous work-up is conducted with a 15% w/w sodium chloride solution at 40 °C, exploiting the temperature-dependent solubility of the coupled biaryl to achieve a single-phase extraction after three cross-current stages in a centrifugal extractor (e.g., Robatel BXP 130). The organic phase is dried over anhydrous magnesium sulfate, filtered through a 0.1 µm PTFE membrane, and concentrated under reduced pressure (25 mbar) with a jacket temperature not exceeding 55 °C to avoid thermal debromination of residual starting material that would liberate corrosive HBr vapour. Terminal products are isolated as crystalline free bases or hydrochloride salts with typical melting point ranges of 172–178 °C and residual solvents passing Class 3 limits per ICH Q3C. Downstream functional group interconversion of the coupled product yields therapeutic candidates, including Type II BCR-ABL inhibitors and investigational EGFR T790M mutant inhibitors, which after formulation into tablet or capsule dosage forms undergo bioequivalence studies referenced against WHO prequalified comparator products. The entire synthesis campaign is documented in a batch record complying with 21 CFR Part 211, with critical process parameters (CPPs) for coupling temperature and catalyst concentration formally revalidated every 15 commercial batches.

Why Does Selective Chloro-Displacement Define the Route to 2-Aminomethyl-5-chlorothiazole?

In the production of neonicotinoid insecticide precursors, the conversion of 2-bromo-5-chlorothiazole to 2-aminomethyl-5-chlorothiazole proceeds through a two-step sequence consisting of nucleophilic substitution with cyanide ion and subsequent catalytic hydrogenation. The cyanation step is executed in a loop reactor equipped with an external shell-and-tube heat exchanger capable of removing 350 W/L of instantaneous heat release; potassium cyanide (or sodium cyanide in cost-driven campaigns) is introduced as a 30% w/v aqueous solution via a dip tube at a rate not exceeding 0.15 L/min per 100 kg of thiazole charge to prevent a pH excursion above 11.2 that accelerates hydrolytic ring-opening of the thiazole nucleus. Operators on a commercial 4 m³ Hastelloy C-276 vessel report that fouling of the pH probe occurs after 12–15 batch cycles due to deposition of [Ni(CN)₄]²⁻ species, necessitating offline cleaning with dilute nitric acid and a cross-check against inline IR spectroscopic data tracking the C≡N stretch at 2170 cm⁻¹. Synthetic crude meeting technical grade specification per FAO Specification 373/TC (Thiamethoxam equivalent for analogous intermediates) requires assay content ≥98.5% and sulfated ash ≤0.2%. The molar charge ratio of potassium cyanide to 2-bromo-5-chlorothiazole is maintained at 1.08–1.12; a lower ratio leads to incomplete conversion and isolation of unreacted bromothiazole that forms a troublesome azeotrope with the product during distillation, while a higher ratio generates excess cyanide ions that poison the heterogeneous hydrogenation catalyst in the downstream amination step. After the cyanation is complete, the organic phase is separated in a decanter centrifuge and the aqueous cyanide-bearing raffinate is oxidised with sodium hypochlorite to cyanate at pH 10.5–11.0 before discharge to the waste treatment plant, in compliance with the effluent limits of category 33/2013/EU for chemical industry wastewater. The isolated 2-cyano-5-chlorothiazole is dissolved in anhydrous methanol (5 volumes) and transferred to a 1000 L Hastelloy B hydrogenation autoclave charged with Raney nickel slurry. Hydrogen pressure is ramped from 2 MPa to 8 MPa over the course of 3 h, maintaining an agitation rate of 800 rpm to ensure k_La values above 0.08 s⁻¹ and complete nitrile reduction; catalyst poisoning by trace cyanide results in an abrupt pressure drop that triggers an interlock stopping the hydrogen feed and activating emergency cooling. The resulting amine is purified by vacuum distillation at 2–4 mbar with a vapour temperature of 114–116 °C, and the distillate is collected in a receiver blanketed with ultrapure nitrogen to prevent carbonate formation. The resultant 2-aminomethyl-5-chlorothiazole is a direct precursor to clothianidin and related neonicotinoid active ingredients formulated as water-dispersible granules containing 500 g/kg active substance, alongside lignosulfonate dispersants and kaolin carriers, for foliar and soil application against sucking pests in cotton and vegetables.

Electrodeficient Heterocycle in All-Organic Emitter Systems

For the synthesis of donor-acceptor (D-A) conjugated polymers employed as the active layer in bulk heterojunction organic photovoltaics, 2-bromo-5-chlorothiazole functions as a terminal end-capping agent that simultaneously introduces a moderately electron-withdrawing heterocycle and a reactive halogen handle for subsequent chain-end modification. Polymer chemists operating in ISO 7 cleanrooms perform Stille polycondensation of a stannylated donor monomer with an acceptor monomer, adding the bromothiazole at 2.0–2.8 mol% relative to total co-monomers when the target number-average molecular weight (M_n) is in the 60–90 kDa window and the dispersity (Đ) must remain below 1.8. Formulation deviations beyond 3.1 mol% induce premature chain termination; gel permeation chromatography traces reveal a low-molecular-weight shoulder that leads to unfavourable π-π stacking distances as measured by grazing-incident wide-angle X-ray scattering, causing a drop in fill factor in the subsequent device. The monomer specification adhered to during semiconductor-grade qualification is SEMI C43-0621, with elemental impurities restricted according to Grade 3 requirements: palladium ≤0.5 ppm, tin ≤1.0 ppm, and zinc ≤0.2 ppm as determined by triple-quadrupole ICP-MS. A single lot of the thiazole end-capper is typically purified by recrystallisation from acetonitrile and two subsequent sublimation cycles at 55 °C under a dynamic vacuum of 10⁻⁴ Pa before its use in a 20 L jacketed polymerisation reactor equipped with a helical ribbon agitator. Reaction monitoring by gel permeation chromatography with multi-angle laser light scattering detection dictates termination when M_n plateaus; the crude copolymer is worked up via precipitation into methanol containing 5% v/v hydrochloric acid to strip residual tin salts, followed by Soxhlet extraction with hexane, dichloromethane, and chlorobenzene sequentially for 24 h each. The purified polymer, fractionated to Mw 80–120 kDa, forms the electron-accepting phase in inverted architecture devices. When blended with a narrow-band gap donor, the resulting photoactive ink is slot-die coated onto flexible PET/ITO substrates at a wet thickness of 20 μm, drying to a solid-state morphology that yields power conversion efficiencies above 8% under AM 1.5G illumination. The end-capped polymer further meets the low-acid-content criterion (acid value <0.02 mg KOH/g) required to prevent corrosion of the PEDOT:PSS hole-transport layer during accelerated aging tests at 85 °C/85% RH per IEC 61215 damp heat protocols. Finished modules are encapsulated with edge sealants possessing a water vapour transmission rate below 10⁻⁴ g/m²·day, targeting lifetime warranties applicable to building-integrated photovoltaic installations.

Generation of 5-chloro-2-thiazolyllithium at –78 °C in anhydrous diethyl ether containing 1.05 eq. of n-butyllithium permits trapping with a diverse set of electrophiles — including DMF (yielding the 2-carbaldehyde), chloroformates, and alkyl chlorosulfates — essential for combinatorial library synthesis in agrochemical discovery. A recurring operational failure observed in jacketed 5 L cylindrical vessels is localised hot-spot formation during BuLi addition when stirring rates fall below 250 rpm; this triggers exothermic runaway to –35 °C within seconds, leading to extensive dimerisation to 5,5'-dichloro-2,2'-bithiazole, which precipitates as a yellow solid and blocks the bottom run-off valve. To mitigate this, process engineers install a Duranit® probe to continuously log temperature across three vertical zones in the reactor and interlock the BuLi dosing pump when the gradient exceeds 12 °C between any two zones. The lithium-halogen exchange proceeds against a quality control framework aligned with ISO 14001 for waste neutralisation: the post-quench aqueous phase, containing lithium and bromide ions, is treated with calcium oxide to precipitate lithium carbonate before sewer discharge. Regarding charge ratio, the thiazole substrate is loaded at 1.0 eq. while n-BuLi titrant concentration is verified by double titration against 2-butanol using 1,10-phenanthroline indicator prior to each production run; a deviation of ±0.02 eq. from the target 1.05 eq. leads to either incomplete conversion (under-charge) or nucleophilic attack on the 5‑chloro position (over-charge) creating 5-butyl-2-bromo-5-chlorothiazole, an impurity with a relative response factor of 0.87 at 220 nm. Downstream, a quench with anhydrous acetone and subsequent pH-controlled hydrolysis delivers the tertiary alcohol intermediate, which is purified by silica plug filtration with EtOAc/hexane 1:4 and then crystallised from methylcyclohexane. The isolated product, typically a single spot on TLC with an R_f of 0.47, meets a purity threshold of ≥97 area% by GC-FID. Such compounds are fed directly into screening cascades for insecticidal lead optimisation against Aphis gossypii, ultimately informing the selection of development candidates that progress to field-trial formulations at 100 g a.i./ha rates. Incompatibilities relevant to the lithium-halogen exchange workflow include the presence of protic solvents or moisture exceeding 30 ppm in the ether, which not only quenches the organolithium but also generates flammable hydrogen gas requiring the explosion-proof nitrogen inerting system to be online and validated before the campaign.

From Heterocyclic Halide to Red-Absorbing Cyanine Dyes

In the dye sector, 2-bromo-5-chlorothiazole serves as a precursor for unsymmetrical trimethine cyanine dyes absorbing in the 600–650 nm range, used principally as fluorescence labels in lateral flow immunodiagnostics. The dye condensation step combines the thiazole quaternary salt (obtained by alkylation with methyl iodide in acetonitrile at 80 °C for 16 h) with a molar equivalent of a 2,3,3-trimethyl-3H-indolinium sulfonate in a mixture of acetic anhydride and triethyl orthoformate, holding the mixture at 95 °C for 45 min. The charge ratio of the thiazole salt to the indolinium component is controlled to 1:1.05; excess thiazole quaternary results in chromatographically inseparable mono-methine by-products that quench fluorescence quantum yield below 0.35. After cooling, the dye mass is precipitated by pouring the reaction mixture into a stirred ten-fold excess of anhydrous diethyl ether held at 0 °C, collected by Büchner filtration through a PTFE-coated filter cloth, and rinsed with additional cold ether until the filtrate exhibits an absorbance <0.05 AU at 590 nm. Dye product destined for biomedical labeling must satisfy heavy metal limits under RoHS Directive 2011/65/EU and California Proposition 65; residual palladium from the quaternisation catalyst or earlier coupling steps must be reduced to ≤2 ppm by treatment with mercaptopropyl-functionalised silica scavengers in a 2% w/w slurry for 6 h at room temperature. The scavenged dye solution is filtered through a 0.2 μm capsule filter and further purified by preparative HPLC using a C18 column (250×50 mm) with isocratic elution in MeCN/water 70:30 containing 0.1% trifluoroacetic acid, achieving a final purity of >98% suitable for bioconjugation. The purified chromophore is then activated as an N-hydroxysuccinimide ester and conjugated to streptavidin under borate buffer at pH 8.5. The resulting conjugate, after dialysis and lyophilisation, is incorporated into test line reagents of rapid diagnostic devices for malaria PfHRP2 antigen detection, requiring a lot-specific extinction coefficient verification at 647 nm in phosphate-buffered saline to guarantee inter-lot signal consistency. From a regulatory standpoint, the entire dye synthesis operating in an ISO 13485-certified facility follows a quality plan that includes batch-specific Certificates of Analysis documenting residual solvent levels compliant with ICH Q3C for Class 2 solvents such as acetonitrile (≤410 ppm).

The preparation of certified reference materials (CRMs) for impurity profiling of thiazole-containing active pharmaceutical ingredients builds on the conversion of 2-bromo-5-chlorothiazole to the corresponding 5-chloro-2-[(4-nitrophenyl)sulfonyl]thiazole via a one-pot palladium-catalysed sulfination with sodium dithionite and subsequent electrophilic trapping with 4-nitrobenzyl bromide. Production follows the general requirements of ISO 17034 (general requirements for the competence of reference material producers) and guidance from USP general chapter ⟨1080⟩ on impurity qualification. The sulfone synthesis is performed in a 10 L Hastelloy reactor pressurised with carbon dioxide to 0.5 MPa, where 2.0 eq. of sodium dithionite and 1.0 eq. of the bromothiazole are combined in a mixture of dimethylformamide and water (4:1 v/v) at 45 °C. The sulfinate intermediate is not isolated; instead, 1.05 eq. of 4-nitrobenzyl bromide is charged in one portion after 3 h, and the reaction proceeds to completion within 8 h. During initial scale-up runs, failure to adequately degas the DMF/water mixture resulted in sulfinate oxidation to sulfonate, reducing sulfone yield by 22% and generating a side-stream that required reprocessing. Consequently, a standard operating procedure mandates sparging the solvent blend with nitrogen through a sintered metal inlet until dissolved oxygen measured by an optical sensor drops below 0.2 mg/L. The crude CRM candidate is purified by repeated recrystallisation from 2-butanone to achieve a chromatographic purity of ≥99.9 area%; homogeneity is assessed by taking a stratified random sample of 20 vials from the beginning, middle, and end of the filling run, each analysed in triplicate. The certified purity value is assigned by the mass balance method, subtracting the sum of residual solvents (by GC headspace per general chapter ⟨467⟩), water (Karl Fischer coulometry), sulfated ash (by thermogravimetric combustion at 600 °C), and related organic impurities from 100.0%. The total combined expanded uncertainty is maintained at ≤0.5% with a coverage factor k=2. End-users in QC laboratories quantify this sulfone derivative by an HPLC method calibrated against the CRM reconstituted to 1.00 mg/mL in acetonitrile, using a mobile phase of acetonitrile/phosphate buffer pH 3.0 and UV detection at 254 nm. This system suitability test is integrated into release testing protocols for thiazole-bearing statin analogues, ensuring that batch-to-batch impurity profiles remain within limits established in the drug master file. Storage of dispensed vials is carried out at –20 °C under argon in amber glass, with a certified shelf life established by real-time stability monitoring over 36 months, thereby eliminating the risk of photolytic or oxidative degradation that could invalidate regulatory submission data.